Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 + MPLA
- Development stage
- Unknown
- Lead developer
- National Institute of Science and Technology of Research in Immunology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal
01
Overview
NY-ESO-1 + MPLA is a therapeutic cancer vaccine composed of the tumor antigen NY‑ESO‑1 and the adjuvant monophosphoryl lipid A (MPLA). NY‑ESO‑1 is a cancer/testis antigen highly immunogenic and expressed in various malignancies, including lung, ovarian, and melanoma. The addition of MPLA, an immunostimulatory adjuvant derived from bacterial lipopolysaccharide (LPS), enhances immune responses by activating Toll-like receptor 4 (TLR4) on antigen-presenting cells. This combination aims to induce robust cellular and humoral immunity against tumors expressing NY‑ESO‑1. Clinical trials have evaluated its safety, tolerability, immunogenicity, and preliminary efficacy in patients with cancers expressing the target antigen[2][4][8].
- Other names
- NY-ESO-1 combined with MPLA vaccineNY-ESO1 combined with MPLA vaccineNY-ESO 1 combined with MPLA vaccine
02
Targets
NY-ESO-1/MHC-I (Major histocompatibility complex class I presenting NY-ESO-1 peptide)TLR4 (Toll-like receptor 4)pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on NY-ESO-1 + MPLA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 + MPLA.